Author:
Pope Janet,Sawant Ruta,Tundia Namita,Du Ella X.,Qi Cynthia Z.,Song Yan,Tang Patrick,Betts Keith A.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference9 articles.
1. Stevenson M, Archer R, Tosh J, et al. Adalimumab, etanercept, infliximab, certolizumabpegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technol Assess (Winchester, England). 2016;20(35):1–610.
2. Baricitinib for moderate to severe rheumatoid arthritis: Technology appraisal guidance. National Institute for Health Care and Excellence (NICE); 2017. Accessed 10 October 2020.
3. Upadacitinib for moderate to severe rheumatoid arthritis. National Institute for Health Care and Excellence (NICE); 2020. https://www.nice.org.uk/guidance/ta665. Accessed 10 Oct 2020.
4. Lee YH, Song GG. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis. Z Rheumatol. 2020;79:785–96. https://doi.org/10.1007/s00393-020-00750-1.
5. Fakhouri W, Wang X, de La Torre I, Nicolay C. A network meta-analysis to compare effectiveness of baricitinib and other treatments in rheumatoid arthritis patients with inadequate response to methotrexate. J Health Econ Outcomes Res. 2020;7(1):10–23.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献